XML 69 R56.htm IDEA: XBRL DOCUMENT v3.22.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details 3) - shares
12 Months Ended
Dec. 31, 2021
Dec. 31, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidiluted earnings per share 3,247,715 2,408,600
Series A Convertible Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidiluted earnings per share [1] 8,000
Series B Convertible Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidiluted earnings per share 764,400
Series B 1 Convertible Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidiluted earnings per share 48,000
Series C Convertible Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidiluted earnings per share 108,600
Series C 1 Convertible Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidiluted earnings per share 865,500
Common Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidiluted earnings per share [2] 1,945,270
Underwriter [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidiluted earnings per share 144,445
Convertible Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidiluted earnings per share [3] 1,158,000 614,100
[1] The Series A the conversion formula is aggregate Stated Value divided by IPO price (State Value for each Series A preferred shares is $1,000). These are 8,000 shares of Series A Preferred Stock issued and outstanding (10,000 shares are designated Series A). The conversion formula would be $8 million (the aggregate stated value) divided by IPO price.
[2] The Board of Directors have approved a 10-years option at an exercise price of $6.49 per share that will be exercisable at any time.
[3] The expiry date of warrants granted with Series C-1 was extended to June 30, 2022.